Dr. Kern is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1400 Jackson St
Denver, CO 80206Phone+1 303-388-4461Fax+1 303-270-2206
Summary
- Dr. Jeffrey Kern is a pulmonologist in Denver, CO and is affiliated with National Jewish Health. He received his medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 38 years. He specializes in critical care medicine, and thoracic oncology and is experienced in lung cancer, pulmonology, critical care medicine, and acute lung injury. He has more than 100 publications and over 6,000 citings.
Clinical Expertise
- General internal medicine, Pulmonology, Critical care medicine, Lung cancer, Thoracic oncology, Kinase signaling, Acute lung injury, ErbB-1 Genes
Education & Training
- University of Pennsylvania Health SystemFellowship, Pulmonary Disease and Critical Care Medicine, 1982 - 1984
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1979 - 1982
- University of Texas Southwestern Medical CenterInternship, Internal Medicine, 1979 - 1980
- University of Wisconsin School of Medicine & Public HealthClass of 1979
Certifications & Licensure
- CO State Medical License 2009 - 2025
- OH State Medical License 2000 - 2010
- IA State Medical License 1988 - 2001
- PA State Medical License 1982 - 1988
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2022
- America's Top Doctors for Cancer Castle Connolly, 2011-2022
- Top MD Consumers Checkbook
Publications & Presentations
PubMed
- 24 citationsApplication of solution equilibrium analysis to in vitro RNA transcription.Jeffrey A. Kern, Robert H. Davis
Biotechnology Progress. 1997-01-01 - 143 citationsDual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.Zhe Tang, Runlei Du, Shan Jiang, Chunying Wu, Deborah S. Barkauskas
British Journal of Cancer. 2008-09-16 - 23 citationsOur current understanding of checkpoint inhibitor therapy in cancer immunotherapy.Elena Goleva, Taras Lyubchenko, Lukas Kraehenbuehl, Mario E. Lacouture, Donald Y.M. Leung
Annals of Allergy, Asthma & Immunology. 2021-03-11
Press Mentions
- Cancer Survivor Credits National Jewish for Early DetectionNovember 2nd, 2022
Grant Support
- Comparative Effectiveness of Limited Resection cs. Stereotactic Body Radiation Therapy for Early Stage Lung CancerNational Cancer Institute2016–2021
- Kinase Dependent Chemotherapy Resistance Mechanisms in Small Cell Lung CancerNational Cancer Institute2016–2018
- Heregulin Signaling in the Injured LungVA2005–2009
- Nrg/Her Restoration Of The Lung Epithelium After InjuryNational Heart, Lung, And Blood Institute2005–2008
- HER Receptor Family, Heregulin And Lung DevelopmentNational Heart, Lung, And Blood Institute2001–2002
- HER Receptor Family, Heregulin And Lung DevelopmentNational Heart, Lung, And Blood Institute1999–2000
- Physician Scientist AwardNational Heart, Lung, And Blood Institute1988–1990
- Physician Scientist AwardNational Heart, Lung, And Blood Institute1986–1987
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: